MCID: MLT095
MIFTS: 16

Multiple Sclerosis 4 malady

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Multiple Sclerosis 4

Aliases & Descriptions for Multiple Sclerosis 4:

Name: Multiple Sclerosis 4 54
Multiple Sclerosis, Susceptibility to, 4 13

Classifications:



External Ids:

OMIM 54 612596

Summaries for Multiple Sclerosis 4

MalaCards based summary : Multiple Sclerosis 4, is also known as multiple sclerosis, susceptibility to, 4. An important gene associated with Multiple Sclerosis 4 is MS4 (Multiple Sclerosis, Susceptiblity To, 4). The drugs 4-Aminopyridine and Interferon beta-1b have been mentioned in the context of this disorder.

Description from OMIM: 612596

Related Diseases for Multiple Sclerosis 4

Symptoms & Phenotypes for Multiple Sclerosis 4

Clinical features from OMIM:

612596

Drugs & Therapeutics for Multiple Sclerosis 4

Drugs for Multiple Sclerosis 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 485)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3,Phase 2,Phase 1 504-24-5 1727
2
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
3
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147245-92-9 3081884
4
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
5
Ziconotide Approved Phase 4 107452-89-1 447451
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
9
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
12
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
13
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
16
Dopamine Approved Phase 4,Phase 2,Phase 3 51-61-6, 62-31-7 681
17
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
18
Dimethyl fumarate Approved, Investigational Phase 4,Phase 2,Phase 3 624-49-7 637568 5271565
19
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 145258-61-3 6438354
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
21
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
24
Glycerol Approved, Experimental Phase 4 56-81-5 753
25 Titanium dioxide Approved Phase 4,Phase 2 13463-67-7
26
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
27
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719
28
Mitoxantrone Approved, Investigational Phase 4,Phase 2,Phase 3 65271-80-9 4212
29 Piracetam Approved Phase 4 7491-74-9
30
Acetylcholine Approved Phase 4,Phase 3 51-84-3 187
31
Donepezil Approved Phase 4 120014-06-4 3152
32
Simvastatin Approved Phase 4,Phase 3,Phase 1,Phase 2 79902-63-9 54454
33
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
34
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2 1972-08-3 16078 2978
35
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
36
Memantine Approved, Investigational Phase 4 19982-08-2 4054
37
Ethanol Approved Phase 4,Phase 3 64-17-5 702
38
Methotrexate Approved Phase 4,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
39
Iron Approved Phase 4 7439-89-6 23925
40
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
41
Calcium carbonate Approved Phase 4 471-34-1
42
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
43
Cetirizine Approved Phase 4 83881-51-0 2678
44
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1 75614-87-8, 51-45-6 774
45
Acetaminophen Approved Phase 4 103-90-2 1983
46
alemtuzumab Approved, Investigational Phase 4,Phase 3,Phase 2 216503-57-0
47
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
48
Ibuprofen Approved Phase 4 15687-27-1 3672
49
Ranitidine Approved Phase 4 66357-59-3, 66357-35-5 3001055
50
Cephalexin Approved, Vet_approved Phase 4 15686-71-2 27447

Interventional clinical trials:

(show top 50) (show all 611)
id Name Status NCT ID Phase
1 Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient Unknown status NCT01407211 Phase 4
2 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4
3 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4
4 Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS) Unknown status NCT01339676 Phase 4
5 Impact of Vitamin A on Multiple Sclerosis (MS) Unknown status NCT01417273 Phase 4
6 Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis Unknown status NCT01705457 Phase 4
7 Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up Unknown status NCT00289159 Phase 4
8 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
9 Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya Unknown status NCT02325440 Phase 4
10 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4
11 Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy Unknown status NCT01992562 Phase 4
12 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
13 Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients Unknown status NCT01772875 Phase 4
14 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
15 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4
16 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4
17 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis Completed NCT02090413 Phase 4
18 Fingolimod -Response According to Coping - Evaluation Completed NCT01420055 Phase 4
19 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device Completed NCT01791244 Phase 4
20 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States Completed NCT01873417 Phase 4
21 A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis Completed NCT01356940 Phase 4
22 The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis Completed NCT00536120 Phase 4
23 fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls Completed NCT00391352 Phase 4
24 Rebif® Rebidose® Versus Rebiject II® Ease-of-Use Completed NCT02019550 Phase 4
25 Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis Completed NCT01480076 Phase 4
26 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
27 Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients Completed NCT01225289 Phase 4
28 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4
29 A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis Completed NCT02064816 Phase 4
30 The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial Completed NCT01034579 Phase 4
31 A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State Completed NCT00744679 Phase 4
32 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients Completed NCT02146534 Phase 4
33 Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment Completed NCT00942214 Phase 4
34 NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness Completed NCT01591551 Phase 4
35 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Completed NCT00246324 Phase 4
36 A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Completed NCT00871780 Phase 4
37 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4
38 Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ (PROCEED) Completed NCT02254304 Phase 4
39 Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients Completed NCT01201343 Phase 4
40 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
41 Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis Completed NCT00367484 Phase 4
42 Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate Completed NCT01454791 Phase 4
43 Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis Completed NCT01310166 Phase 4
44 Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Completed NCT02142205 Phase 4
45 Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers Completed NCT00913666 Phase 4
46 Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4
47 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany Completed NCT02125604 Phase 4
48 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
49 FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra Completed NCT01656148 Phase 4
50 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4

Search NIH Clinical Center for Multiple Sclerosis 4

Genetic Tests for Multiple Sclerosis 4

Anatomical Context for Multiple Sclerosis 4

Publications for Multiple Sclerosis 4

Variations for Multiple Sclerosis 4

Expression for Multiple Sclerosis 4

Search GEO for disease gene expression data for Multiple Sclerosis 4.

Pathways for Multiple Sclerosis 4

GO Terms for Multiple Sclerosis 4

Sources for Multiple Sclerosis 4

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....